Checkmate Pharmaceuticals Net Income

Checkmate Pharmaceuticals posts a net income of $-63M as of March 2022. That compares with $-43M in the prior-year period — down 46.1% year over year. That is below the Healthcare sector average of $16B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Checkmate Pharmaceuticals's net income was $-43M. The latest reading is $-63M — a 46.1% year-over-year decrease (period ending March 2022). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a net income near $16B is typical. Checkmate Pharmaceuticals's $-63M is lower that level. That is roughly 100.4% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Net Income is one piece of Checkmate Pharmaceuticals's financial statement story. At $-63M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for CMPI's net income usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $16B), and (3) consistency with growth and profitability. This page covers the first two; Checkmate Pharmaceuticals's other metric pages and overview cover the third.